Kolexia
Bonichon-Lamichhane Nathalie Oncologie radiothérapie
Bonichon-Lamichhane Nathalie
Oncologie radiothérapie
Polyclinique de Bordeaux Tondu
Bordeaux, France
75 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Adénocarcinome Tumeurs du sein Tumeurs du rectum Carcinome épithélial de l'ovaire Tumeurs colorectales Métastase tumorale Récidive tumorale locale Tumeurs de l'oesophage

Collaborateurs

Voir plus
Garbay Delphine
Garbay Delphine
Polyclinique de Bordeaux Tondu, Bordeaux, France
Debelleix Christophe
Debelleix Christophe
Polyclinique de Bordeaux Tondu, Bordeaux, France
Susperregui Jocelyn
Susperregui Jocelyn
Polyclinique de Bordeaux Tondu, Bordeaux, France
Celhay Olivier
Celhay Olivier
Polyclinique de Bordeaux Tondu, Bordeaux, France

Industries

Voir plus
AstraZeneca
6 collaboration(s)
Dernière en 2023
MSD
6 collaboration(s)
Dernière en 2023
Servier
5 collaboration(s)
Dernière en 2023
Amgen
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data.
Breast (Edinburgh, Scotland)   22 décembre 2023
NeoTOP: Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer
Essai Clinique (Unicancer)   06 décembre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
Néofirinox: Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer
Essai Clinique (Unicancer)   30 août 2023
Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.
Cancers   06 avril 2023
TEDOPAM: A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Plus FOLFIRI, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM-D17-01 PRODIGE 63 Study)
Essai Clinique (Ose Immunotherapeutics)   24 février 2023
59P Expression of CD47 a potent ‘don’t eat me signal' in ovarian cancer (OC): Correlation with other immune features and evolution under neoadjuvant chemotherapy (NACT), a GINEGEPS study
Abstract Book of the ESMO Gynaecological Cancers Congress, Barcelona, Spain, 23-24 February 2023   01 février 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecologic oncology   25 janvier 2023
1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022